You are here: Industry Insights > ADC

News List

Zydus launches Ujvira (trastuzumab emtansine) for breast cancer treatment expresspharma
May 25, 2021
Zydus Cadila launched Trastuzumab Emtansine, an antibody-drug conjugate (ADC) biosimilar and a drug for treating both early and advanced HER2 positive breast cancer, under the brand name ‘Ujvira’.
Sterling Pharma Appoints Stewart Mitchell as New Site Head contractpharma
May 25, 2021
Sterling Pharma Solutions, a global CDMO, has appointed Stewart Mitchell as site head of its new antibody-drug conjugate (ADC) facility in Deeside, UK. Dr. Mitchell will lead the Deeside facility, and report to Kevin Cook ...
GeneQuantum Raises Hundreds of Millions RMB in Series C Funding prnasia
May 19, 2021
GeneQuantum Healthcare (Suzhou) Co., Ltd. announced the completion of Series C fund raising of several hundreds of millions RMB.
Novasep Expands HPAPI Manufacturing Capacity contractpharma
May 14, 2021
Novasep has expanded its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities on its Le Mans, France site.
FDA Approves ADC Therapeutics' Zynlonta contractpharma
May 08, 2021
ADC collaborated with CDMO Sterling Pharma Solutions to develop the cancer drug.
ADC Therapeutics gets USFDA nod for ZYNLONTA to treat relapsed or refractory diffuse large B-cell lymphoma expresspharma
April 26, 2021
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Qilu Pharmaceutical and Peptron Sign License Agreement for anti-MUC1 ADC prnasia
April 19, 2021
Peptron, Inc., a South Korea-based biotech company, and Qilu Pharmaceutical, a leading vertically integrated pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines announced that the companies ...
Sterling Pharma Solutions Acquires ADC Biotechnology contractpharma
April 08, 2021
Global contract development and manufacturing organization (CDMO), Sterling Pharma Solutions, has acquired ADC Biotechnology, a UK-based bioconjugation development services business specializing in antibody drug conjugates (ADCs).
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors americanpharmaceuticalreview
April 07, 2021
Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with ...
Eisai Begins Construction of New Injection/Research Building contractpharma
March 23, 2021
Eisai Co., Ltd., as part of a strategic investment, began construction of a new injection/research building "Eisai Medicine Innovation Technology Solutions" (EMITS) at the Kawashima Industrial Park in Gifu Prefecture, Japan.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page